| Document |
Document Title |
|
WO/2019/029129A1 |
A dual-specificity hybrid protein for IL-17 and TNF-α, and a preparation method and uses thereof. The present dual-specificity hybrid protein for IL-17 and TNF-α is a dimer respectively comprising three structural function areas, said ...
|
|
WO/2019/028504A1 |
The present invention relates to sensors and methods for detecting carbohydrates, such as lactose, in a sample. The sensors and methods may also be used to determine the amount of carbohydrate in the sample.
|
|
WO/2019/029713A1 |
Provided is a method of using a CHO host cell with an edited genome in producing a recombinant antibody having a unique glycan profile. The method uses TALEN technology to edit fut8 gene of a CHO cell that has been adapted to serum-free ...
|
|
WO/2019/028530A1 |
A recombinant, humanized antibody or antibody fragment that is capable of at least partly preventing or inhibiting Epstein Barr Virus gp350 binding to a human cell. The antibody may be useful for passively immunizing humans against Epste...
|
|
WO/2019/028686A1 |
Provided are a donor construct, a gene knockout method, and a system and a kit thereof. Said donor construct is a linear donor DNA or can be cleaved in a cell to produce the linear donor DNA. The gene knockout method uses a marker gene c...
|
|
WO/2019/028994A1 |
Provided is an application of a lettuce as a host in the expression of a nerve growth factor. Further provided are a recombinant vector comprising a nucleotide sequence and a binary plant vector of a nerve growth factor (NGF), and a meth...
|
|
WO/2019/028993A1 |
Provided is application of a lettuce as a host in expressing a factor. Anti-hemophilic factor VIII (FVIII) is expressed using a recombinant vector by means of agrobacterium-mediated vacuum infiltration. The expression system determines t...
|
|
WO/2019/027364A1 |
The present invention related to the provision of genetically modified fungal cells, such as yeast cells with an improved ability for producing and secreting different recombinant proteins. The improved ability is obtained by disruption ...
|
|
WO/2019/025565A1 |
The present invention pertains to dual inhibition of Inhibitor of κB Kinase (IKK) 1 and IKK2 in a biological cell for the treatment of tumors. The invention provides compositions comprising IKK1 and IKK2 antagonists for use in medical t...
|
|
WO/2019/028381A1 |
There is described a method for extracting a target chemical compound from a cellular material in a sample. The method comprising the steps of: subjecting the sample to mechanical lysis to cause disruption of a cellular membrane in the c...
|
|
WO/2019/026924A1 |
Provided are a new powdery mildew resistance marker of Cucurbita maxima, powdery-mildew-resistant Cucurbita maxima, and a method for producing powdery-mildew-resistant Cucurbita maxima in which the same is used. This powdery mildew resis...
|
|
WO/2019/028051A1 |
Chimeric antigen receptors containing CD19/CD20 or CD20/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the ch...
|
|
WO/2019/027869A1 |
Provided herein are genetic circuits and encoded RNA transcripts that produce an output molecule in response to an RNA cleavage event that removes a degradation signal. In some embodiments, the genetic circuits described herein may be us...
|
|
WO/2019/028306A2 |
The invention provides compositions and methods for the preparation, manufacture, formulation and therapeutic use of adeno-associated virus (AAV) particles for the prevention and/or treatment of diseases.
|
|
WO/2019/024706A1 |
An aspartase variant, a preparation method therefor, and an application thereof are provided. The amino acid sequence of the aspartase variant has 96% or higher identity with sequence 2 in the sequence listing, comprises T187I and N326C ...
|
|
WO/2019/028419A1 |
Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjug...
|
|
WO/2019/025908A1 |
Myosin heavy chain 11 (MYH11)-siRNA-eluting, calponin 1 (CNN1)- siRNA-eluting, leiomodin 1 (LMOD)-siRNA-eluting, smoothelin (SMTN)- siRNA-eluting, tropomyosin (TPM)-siRNA- eluting, caldesmon 1 (CALD)- siRNA-eluting, actinin (ACTN)-siRNA-...
|
|
WO/2019/028246A2 |
In certain embodiments the present invention provides a method of treating hearing loss comprising: (a) administering a gene suppression agent that suppresses both copies of an endogenous gene causing the hearing loss; and (b) administer...
|
|
WO/2019/027790A1 |
The invention provides three novel disarmed strains of Agrobacterium tumefaciens bacteria useful for the transformation of plants. The invention provides three engineered A. tumefaciens Chry5 strains or bacterial cells thereof which comp...
|
|
WO/2019/024534A1 |
Disclosed are a rice ALS mutant protein for conferring herbicide resistance to plants, and a nucleic acid encoding the protein. The protein is derived from a rice mutant plant resistant to an ALS inhibitor herbicide, and compared to the ...
|
|
WO/2019/026082A1 |
A recombinant protein, including: (a) alpha subunit of an FAD-GDH; and (b) a minimal cytochrome c peptide is provided. Additionally, an electrode coupled to a recombinant protein, the recombinant protein made of: (a) a cofactor of a redo...
|
|
WO/2019/028462A1 |
Embodiments of a method and/or system for facilitating characterization of one or more conditions can include: generating a set of target-associated molecules; generating a reference-associated set of molecule; facilitating generation of...
|
|
WO/2019/026920A1 |
Provided is a method for presenting a cyclic peptide, which has a chemically crosslinked structure for forming an intramolecular cyclic structure, on a protein having a loop structure, said method comprising substituting the chemically c...
|
|
WO/2019/026976A1 |
Modified CjCas9 proteins that can better bind to guide RNA and are useful as tools for gene editing. For example, a protein that can bind to guide RNA and comprises a sequence that includes the amino acid sequence represented by SEQ ID N...
|
|
WO/2019/026517A1 |
The objective of the present invention is to provide a versatile method that makes highly sensitive detection of nucleic acid, and the like, possible even if a solution has a high salt concentration. This objective has been achieved thro...
|
|
WO/2019/024150A1 |
Provided in the present invention are a transcription factor composition comprising transcription factors ELL, AFF and CRTC. A mammalian protein expression system may be obtained by co-transfecting an expression vector comprising a gene ...
|
|
WO/2019/027871A1 |
Genetic constructs are provided to reduce or eliminate the allergenicity of peanuts. The constructs function by generating interfering RNA and/or by directing deletion using the CRISPR/Cas9 system. The constructs may be used in the produ...
|
|
WO/2019/027728A1 |
Compositions comprising synthetic two-part aptamer-containing guide RNAs and methods of using said synthetic two-part aptamer-containing guide RNAs with CRISPR/Cas activator systems.
|
|
WO/2019/028094A1 |
The present invention provides an isolated population of cortical bone stem cell (CBSC)-derived exosomes, and compositions comprising the exosomes and/or RNA thereof, for promoting cardiac repair when delivered to a diseased heart.
|
|
WO/2019/027015A1 |
The present invention provides a nucleic acid complex represented by formula 1, the nucleic acid complex being capable of suppressing the expression of complement factor B (CFB). Formula 1: (in formula 1, X is a double-stranded nucleic a...
|
|
WO/2019/026948A1 |
[Problem] To provide a vector including a transcription factor and a promotor expressed specifically in the fiber structure of a plant, particularly cotton. [Solution] A vector including at least one promotor expressed specifically in co...
|
|
WO/2019/028032A1 |
Methods and compositions are provided herein for assessing CRISPR/Cas-mediated non-homologous end joining (NHEJ) activity and/or CRISPR/Cas-induced recombination of a target genomic locus with an exogenous donor nucleic acid in vivo and ...
|
|
WO/2019/028029A1 |
Methods and compositions are provided for assessing CRISPR/Cas-induced recombination of a target genomic locus with an exogenous donor nucleic acid in vivo or ex vivo. The methods and compositions employ non-human animals comprising a CR...
|
|
WO/2019/027298A2 |
The present invention relates to a pharmaceutical composition comprising mesenchymal stem cells expressing TRAIL and CD as an effective ingredient for prevention or treatment of cancer. A pharmaceutical composition comprising TRAIL- and ...
|
|
WO/2019/024341A1 |
A method for constructing a library of cell-free DNAs in body fluids, comprising directly acting a transposase or an endonuclease on a body fluid sample, fragmenting the cell-free DNAs within, and performing amplification to obtain a lib...
|
|
WO/2019/028417A1 |
Methods and systems are described herein for generating engineered B cells with modified immunoglobulin genes. The modified immunoglobulin genes encode modified immunoglobulins that can have high affinity for antigens, including antigens...
|
|
WO/2019/027299A2 |
The present invention relates to a pharmaceutical composition for preventing or treating vascular disorders including a mesenchymal stem cell expressing a hepatocyte growth factor (HGF) protein as an active ingredient. This pharmaceutica...
|
|
WO/2019/028355A1 |
Endophytic bacteria, compositions comprising the same, and methods of use thereof are disclosed which increase the root and shoot growth of cotton host plants, suppress growth of soil borne fungal pathogens of host plants, and increase r...
|
|
WO/2019/023917A1 |
A biomarker, the use of the biomarker in predicting the risk of atherosclerotic cardiovascular disease or related disorder thereof, and a method of predicting the risk of atherosclerotic cardiovascular disease or related disorder thereof.
|
|
WO/2019/023770A1 |
The present invention describes a composition for gene therapy of the central nervous system comprising nonviral nanoscale (<1.0 micrometer) carriers complexed with at least one nucleic acid for purposes of gene therapy via nasal adminis...
|
|
WO/2019/027987A2 |
The present disclosure relates to compositions and methods for treating cancers. In particular, the present disclosure provides materials and methods for identifying mis-splicing-associated surface antigens (MASAs) generated by altered s...
|
|
WO/2019/025800A1 |
The present invention provides a cell which expresses a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR), the cell comprising a nucleotide sequence of interest (NOI) which is selectively expressed by the cell depend...
|
|
WO/2019/026884A1 |
Provided is a method for rapidly detecting a nucleic acid. This nucleic acid detection method involves detecting a nucleic acid of interest from a fluid containing a nucleic acid of interest, wherein: the method is provided with a detect...
|
|
WO/2019/023806A1 |
A plant or plant cell with reduced endogenous AGO1 and AGO4 expression compared to a wild-type plant or plant cell is provided. In one embodiment, the plant or plant cell further comprises a nucleic acid sequence encoding a recombinant p...
|
|
WO/2019/027005A1 |
Provided is a method for evaluating an onset risk of tuberculosis on the basis of genetic information of a subject, said subject being infected with Mycobacterium tuberculosis, specifically to each genetic lineage of M. tuberculosis. The...
|
|
WO/2019/028273A1 |
The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel elements that further improve expression. The gene transfer systems can be used in methods, for example,...
|
|
WO/2019/025984A1 |
Cellular models for diseases of eyes, methods and compositions for treating diseases in eyes are provided.
|
|
WO/2019/028426A1 |
The present disclosure relates to bifunctional chemical epigenetic modifiers, and methods of making, kits and using the bifunctional chemical epigenetic modifiers. The bifunctional chemical epigenetic modifiers can include a FK506 molecu...
|
|
WO/2019/027789A1 |
The present invention relates to methods and compositions for chimeric RNA comprising a guide RNA and bait RNA for modifying a target site in the genome of a cell. Such modifications include integration of a transgene and allelic mutatio...
|
|
WO/2019/028125A1 |
This disclosure relates to bispecific antibodies or antigen-binding fragments thereof, wherein the bispecific antibodies or antigen-binding fragments thereof specifically bind to two different antigens with different binding affinities.
|
